Evaluation of Soluble Mesothelin-related Peptide as a Diagnostic Marker of Malignant Pleural Mesothelioma Effusions: Its Contribution to Cytology

被引：21

作者：

Canessa, Pier Aldo ^{[1
]}

Franceschini, Maria Cristiana ^{[2
]}

Ferro, Paola ^{[2
]}

Battolla, Enrico ^{[3
]}

Dessanti, Paolo ^{[2
]}

Manta, Carmen ^{[1
]}

Sivori, Massimiliano ^{[1
]}

Pezzi, Riccardo ^{[4
]}

Fontana, Vincenzo ^{[4
]}

Fedeli, Franco ^{[2
]}

Pistillo, Maria Pia ^{[5
]}

Roncella, Silvio ^{[2
]}

机构：

[1] Div Pneumol, La Spezia, Italy

[2] Div Histopathol & Cytopathol, La Spezia, Italy

[3] Div Clin Pathol ASL5, La Spezia, Italy

[4] IRCCS AOU San Martino IST, Epidemiol Biostat & Clin Trials Unit, Genoa, Italy

[5] IRCCS AOU San Martino IST, Tumor Genet & Epigenet Unit, Genoa, Italy

来源：

CANCER INVESTIGATION | 2013年 / 31卷 / 01期

关键词：

Cytology; ELISA; Mesothelin; Mesothelioma; Pleural effusion; Tumor; CLINICAL-SIGNIFICANCE; LUNG-CANCER; BIOMARKERS; EXPERIENCE; MANAGEMENT; PROTEINS; FLUID; SERUM;

D O I：

10.3109/07357907.2012.749265

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Soluble mesothelin-related peptide (SMRP) is regarded as an FDA approved biomarker for the diagnosis and monitoring of pleural malignant mesothelioma (MPM). We detected the SMRP levels in pleural effusions (PE) by means of an ELISA and analyzed their diagnostic relevance to differentiate MPM from benign pathology and from non-MPM pleural metastasis. Comparison with cytology in MPM-PE was also performed. We found that SMRP detection in MPM-PE can help the diagnosis of MPM and provide additional diagnostic value to cytology. We concluded that SMRP test may be incorporated into clinical practice of PE from patients suspicious for MPM.

引用

页码：48 / 55

页数：8

共 26 条

[21] Serum soluble mesothelin-related protein (SMRP) and fibulin-3 levels correlate with baseline malignant pleural mesothelioma (MPM) tumor volumes but are not useful as biomarkers of response in an immunotherapy trial
Katz, Sharyn, I
Roshkovan, Leonid
Berger, Ian
Friedberg, Joseph S.
Alley, Evan W.
Simone, Charles B., II
Haas, Andrew R.
Cengel, Keith A.
Sterman, Daniel H.
Albelda, Steven M.
LUNG CANCER, 2021, 154 : 5 - 12
[22] miR-130A as a diagnostic marker to differentiate malignant mesothelioma from lung adenocarcinoma in pleural effusion cytology
Cappellesso, Rocco
Galasso, Marco
Nicole, Lorenzo
Dabrilli, Paolo
Volinia, Stefano
Fassina, Ambrogio
CANCER CYTOPATHOLOGY, 2017, 125 (08) : 635 - 643
[23] Soluble oncoprotein 185HER-2 in pleural fluid has limited usefulness for the diagnostic evaluation of malignant effusions
Porcel, JM
Salud, A
Vives, M
Esquerda, A
Rodríguez-Panadero, F
CLINICAL BIOCHEMISTRY, 2005, 38 (11) : 1031 - 1033
[24] WIF-1 promoter region hypermethylation as an adjuvant diagnostic marker for non-small cell lung cancer-related malignant pleural effusions
Yang, Tsung-Ming
Leu, Shaw-Wei
Li, Jhy-Ming
Hung, Ming-Szu
Lin, Chu-Huan
Lin, Yu-Ching
Huang, Tung-Jung
Tsai, Ying-Huang
Yang, Cheng-Ta
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2009, 135 (07) : 919 - 924
[25] WIF-1 promoter region hypermethylation as an adjuvant diagnostic marker for non-small cell lung cancer-related malignant pleural effusions
Tsung-Ming Yang
Shaw-Wei Leu
Jhy-Ming Li
Ming-Szu Hung
Chu-Huan Lin
Yu-Ching Lin
Tung-Jung Huang
Ying-Huang Tsai
Cheng-Ta Yang
Journal of Cancer Research and Clinical Oncology, 2009, 135 : 919 - 924
[26] Comprehensive immunohistochemical study of mesothelin (MSLN) using different monoclonal antibodies 5B2 and MN-1 in 1562 tumors with evaluation of its prognostic value in malignant pleural mesothelioma
Inaguma, Shingo
Wang, Zengfeng
Lasota, Jerzy
Onda, Masanori
Czapiewski, Piotr
Langfort, Renata
Rys, Janusz
Szpor, Joanna
Waloszczyk, Piotr
Okon, Krzysztof
Biernat, Wojciech
Ikeda, Hiroshi
Schrump, David S.
Hassan, Raffit
Pastan, Ira
Miettinen, Markku
ONCOTARGET, 2017, 8 (16) : 26744 - 26754

← 1 2 3 →